NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
NeuroBo Pharmaceuticals Doses First Patient in MAD Part 2 of Phase 1 Trial for DA-1726 in Obesity Treatment; Top-Line Data for Part 1 Expected Q3 2024, Part 2 in Q1 2025; Planned Part 3 to Assess Weight Loss at 24 Weeks; $70M Financing to Fund Ongoing...
neurobo pharmaceuticals 在肥胖治療DA-1726的一期試驗MAD第二部分中給第一名患者注射劑量;第一部分的最終數據預計於2024年第3季度公佈,第二部分預計於2025年第1季度公佈;計劃的第三部分將評估24周的體重減輕情況;$70M融資將用於持續進行...